November 2, 2021 -- Swedish liquid biopsy and genomic testing provider Saga Diagnostics is developing new digital polymerase chain reaction (dPCR) assays for AstraZeneca.
Under the deal, Saga will create unique versions of its Sagasafe dPCR assays toward undisclosed methylated targets for analyses of tissue samples and liquid biopsies, according to the company. AstraZeneca will utilize the assays in a clinical research study.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current